GSE162915
Clinical optimization and molecular characterization of an engineered Type-1 regulatory T cell therapy
purpose: To investigate transcriptional changes in engineered Tr1 Cells Methods: RNA sequencing of polyA enriched donor matched CD4 T cells lentiviral transduced with human IL-10 (CD4IL-10) or control GFP (CD4GFP) Results: 142 total DEGs were identified as differentially expressed between CD4IL-10 and CD4GFP. GEO analysis found highest enrichment in genes related to cytokine signaling and cytotoxicity. Conclusion: Engineered Tr1 cells upregulate primarily cytotoxicity related effector molecules related to the myeloid cell killing phenotype observed in Tr1 cells Overall design: 4 donor matched pairs of of CD4GFP and CD4IL-10 were incubated for 2h in complete X-VIVO15 and then lysed for RNA sequencing